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ABSTRACT
Up to about the early 1980s it was perhaps still possible to summarize in a review of a moderate
length the development of the medicinal applications of chelation chemistry and the exploitation of
such chemistry in regulating the metal ion concentrations in the body. However, in the last few years
there has a great surge in the development of chelation chemistry and its usage in medicine and
related areas of life sciences research. It is no longer the case that such a review primarily
concentrates upon the use of chelating agents in removing toxic metals from the body but it must
now cover the use of chelating agents in the imaging procedures nuclear medicine and magnetic
resonance imaging (MRI), the use of chelating agents in unravelling the biochemistry of reactive
oxidative species (ROS) and the control and measurement of intracellular calcium ions. It is in the
recent applications that there have been the greatest developments over the last ten years.
INTRODUCTION: THE CONTINUING DEVELOPMENT OF CHELATION CHEMISTRY IN MEDICINE
The essentiality of several trace metals for our good health is well recognized but in more recent
years many metal compounds have also been recognized as environmental and work-place
carcinogens (1, 2 and reviews therein). These observations, the use of chelated metal ions in
non-invasive diagnostic medical procedures, such as nuclear medicine and MRI, the need to control
the levels of toxic metal ions in the body and the search for inorganic drugs other than cisplatin and
auranofin have led to extensive developments in chelation chemistry. Although inorganic drugs are
always going to be minor components of a pharmacopoeia, it is possible that they might become
important therapies forsome significant diseases such as diabetes which in western industrial nations
has an incidence of 1 in 300 (3). Although insulin replacement is the easiest method of controlling
chronic diabetes the only satisfactory route of administration is by injection and this has prompted
the search for orally deliverable therapies. Currently much interest has been shown in the inorganic
biochemistry of vanadium as in some forms it is an orally active insulin mimetic (4). Although
vanadate is active, its uptake from the gastrointestinal tract is low but vanadyl bis-maltolato is orally
active and is a powerful insulin mimetic (5). The recently reported metabolic problems ascribed to
vanadium in Thais dwelling in regions with vanadium-rich soils (6) should be studied in depth before
the launch of vanadium-containing pharmaceuticals.
It is clear from studying the literature on inorganic biochemistry in its widest forms, from the
speciation of metal ions to investigations of the clearance of toxic metal ions from the body, that
many novel approaches have been used to modify the behaviour of the biological response to metal
ions. Although low molecular weight chelating agents have been the major mechanism for modifying
biological response to metal ions, other procedures which exploit metalloproteins are almost certainly
going to become feasible as genetic engineering develops. Already of note has been the production
of an antibody which bears a functioning metallothionein which can be loaded with cationic 99mTc
and then targeted to cells (7). The recent considerations about metallothionein and cancer (8) might
lead to further investigations of such genetic engineering.
The reasons for giving serious consideration to the contribution of inorganic elements to mammalian
biochemistry continue to grow and it is clearly unwise to assume there is a full understanding of
mammalian biochemistry because of the use metabolic pathways as vanity boards in laboratories
and offices. The continuing development of analytical instrumentation is likely to lead to the
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identification of more essential trace elements or the concentration of elements in diseased tissue.
For instance, by using particle induced X-ray emission spectroscopy strontium was identified in the
granulocytes of patients with rheumatoid arthritis and shown to fall from 5.1 pg/g dry weight to 1.7
pg/g over a three month course of treatment with anti-inflammatory drugs (9). The extent to which
chelating agents have continued to be the subject of study in biochemistry and medicine can be
judged from Table 1 which was compiled from an on-line search of Med/ine using the search terms
chelat* and the names of various chelating agents. Unfortunately because of the way the files on
the Medline database are currently constructed it is impossible to summarize the data for a sequence
of, say five years, by other than an much more expensive search. By using some additional terms
it has also been to obtain some idea of the number of publications in which D-penicillamine was likely
to have been discussed primarily in the treatment of rheumatoid arthritis. From the number of hits
for 1985-89 and from 1990 to July 1993 it is clear that research applications of chelating agents in
medicine and the relevant life sciences shows no sign of declining but is actually increasing. By the
mid-1960s the initial use of chelating agents in medicine as almost a panacea had practically
stopped, so it might be presumed that the hits for the years from 1966 onwards primarily reflect
accounts of their use for chelation of metal ions in medicine and the relevant life sciences. No
doubt many of these uses in life sciences reflect the development of inorganic biochemistry.
Table 1 Summation of hits from an on-line search of Medline for the various chelating agents listed
below
Years NUMBER OF HITS FOR THE SEARCH TERMS BELOW
Chelating EDTA DTPA DFOA DMSA DMPS BAL DDC PEN
agent
PEN# PEN#
Chelat Rheuma
66-84 21950 14429 1388 954 247 40 100 46 1279 1162 467
85-89 7109 4070 1558 917 235 49 28 47 498 399 192
90-93 7639 3529 1985 915 314 49 31 48 338 221 104
Respectively ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, desferrioxamine,
2,3-di-mercaptosuccinic acid, 2,3-dimercaptopropane sulphonic acid, 2,3-dimercaptopropanol,
diethylenedithio-carbamic acid and D-penicillamine.ote BAL was not used as the search term but
instead the search term was dimercaptopropano/; Combined respective search terms D-PEN +
chelat and D-PEN + rheuma
In this account the development of chelation chemistry is summarized by highlighting its exploitation
in the following uses:
(a)
(b)
(c)
(d)
(e)
As counter measures to the uptake of toxic metals, uses reviewed over many years and
summarized elsewhere in 1987 (10) and in 1991 (11,12).
In non-invasive diagnostic medicine as vehicles for the transport of radionuclides such as
99mTc 67Ga 1111n used in nuclear medicine and more recently paramagnetic species,
primarily Gd3+, in MRI’,
As targeting agents in radiotherapy, particularly when bound to macromolecules such as
monoclonal antibodies;
As anti-microbials, anti-malarials, anti-virals, anti-neoplastic agents and anti-parasitic agents;
In investigations of free radical chemistry.
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OCCURRENCE OF CHELATING AGENTS
It is well recognized that many low molecular weight chelating agents of considerable diversity occur
in nature and practically all of the more common chelating moieties, other than dithiocarbamate and
vicinal dithiols, have been observed in nature, particularly as extracellular products of the protista.
Even the N-CH2COOH moiety of the polyaminopolycarboxylic acids (PAPCs) and 2,2’-bipyridyl are
to be found in nature in pyridine-2,6-dicarboxylic acid and bipyridyl-containing caerlomycin (13). In
a recent extensive review, well worth detailed study, Michael and Pattenden have taken a critical
look at potential metal ion chelation by marine metabolites (14). In man regulation of the
concentration of metal ions is achieved primarily by uptake by macromolecules such as transferrin,
ferritin, metallothionein, caeruplasmin and, rather weakly, by serum albumin. Regulation of metal
ions by low molecular weight chemicals appears to be primarily by citrate and amino acids. The
extent to which an interaction of adrenaline, the possessor of the o-catechol moiety, with copper(ll)
and iron(l I) has any significance in our wellbeing, or perhaps lack of it, is still to be demonstrated
as catecholamines are prone to autooxidation in the presence of transition metal ions. The
occurrence of 3,4-dihyroxyphenylalanine in the primary sequence of some proteins has been noted
(15) but the participation of this moiety in metal-binding has yet to be determined. The occurrence
of vanilmandelic acid in neuroblastoma has been noted (16) as has the occurrence of a siderophore-
growth factor in virally transformed cells (17). A role for higher aliphatic 2,4-diketones, a ubiquitous
lipid family with chelating properties, is still being sought, although it is recognized that they exhibit
anti-allergic and antihistamine properties (18).
METAL IONS IN CELLS
As Sorenson (19) has indicated, complexes and chelates of metal ions are the biologically relevant
forms of the metalloelements as they produce identifiable pharmacological effects. The
concentrations in plasma of essential transition trace elements, as free ions, are low and have had
to been estimated by computer simulation studies (20). Of the major potentially chelatable cations
in plasma the concentration of Mg
2/ and Ca2. is several orders of magnitude higher (20) than the
next most abundant species listed in Table 2. Also summarized in Table 2 is the amount of the
element in a 70 kg standard man and the number of atoms per cell (21). It is presumed that the
concentrations of ionically bonded transition metal ions in cells are much lower than the
concentrations in plasma as cells have much higher concentrations of covalent and
coordinate-covalent bonding ligands.
Table 2 Amounts of the major chelatable elements in plasma, in cells and in standard 70 kg man
Mg Ca Mn Fe Cu Zn
Molarity in plasma 5.2 E-4 E-3 E-12 E-23 E-18 E-9
Grams per 70kg 35 1050 0.02 4.2 0.11 2.33
No of atoms per cell 8.7 E9 1.6 Ell 2.2 E12 4.5 E8 1 E7 2.2 E8
METAL ION REGULATION BY DRUGS NOT SPECIFICALLY DESIGNED AS CHELATING
AGENTS
Perturbations of metal ions during medication are recognized and in some cases might be the
unwanted side-effects of the drugs. In general organic drugs, other than chelating agents, are not
designed to have appreciable metal-binding properties and little attention has been paid to the
perturbation of metal ion concentration through normal medical treatment (22). Although changes in
trace element concentration can be the intended result of therapy, they are more often the result of
side-effects which are unintentional sequellae of the therapy. No doubt there are many unrecognized
alterations in trace element concentrations during treatment and presumably these concentrations
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return to normal after the end of the treatment. Alterations in trace element concentrations are only
likely to be noted in cases where the therapy is very long term or if the side-effect is so drastic that
it manifests itself early in the treatment. All organic compounds containing heteroatoms that have
donatable lone pairs of electrons are potentially capable of interacting with metal ions. By and large
the rigorous testing procedures used in drug development should not lead to the marketing of drugs
with such unwanted side effects as major or long term alterations in the concentrations of trace
element. By determining the formation constant of a complex formed between a potential drug and
a series of metal ions and also knowing the formation constants for the complexes formed between
metal ions and biochemical ligands, it is possible to makepredictions of the extent to which the
chemical might alter the normal distribution of metal ions in fluids such as plasma. These procedures
became available in the late 1970s (20) when computer programs were developed which permitted
high speed calculations to be run so that the distribution of metal ions between several compartments
could be determined. These computer simulation models have shown EDTA in plasma exists
primarily as the calcium chelate with the exception of 15% present as the zinc chelate (23). In
contrast, DTPA exists primarily in plasma as the zinc chelate.
Only a few cases of the interaction drugs with metal ions are given here as this lecture is primarily
a summary of the biomedical applications of chelating agents. Acquirement of anti-inflammatory
properties by anthranilic acid and 3,5-diisopropylsalicylic acid arises only on complexation of
copper(I I) while other anti-inflammatories such as aspirin and D-penicillamine are more active as their
copper(ll) complexes (24). The chelation of essential trace elements by salicylates might well become
significant developments worth using in radiotherapy. Currently studies by Sorenson are indicating
that complexes of first row transition metal ions with anti-inflammatories, such as
3,5-di-isopropylsalicylate, can increase dramatically the survival rate of gamma-irradiated mice (25).
Although metal ion-binding functions are not normally significant moieties in drugs, they have been
incorporated into the structure ofthe non-steroidal anti-inflammatory drugs which generally exert their
effect by binding copper(ll). Isoxicam (Fig. la), now withdrawn because of its purported side-effects,
possesses the I-diketone metal-binding moiety as well as the sulphoxide ligand (26). Treatment of
epilepsy with phenytoin (Fig. l b) leads to alterations in copper and zinc metabolism (27).
Interestingly, a few years before this report, Weismann et al (28) had reported a greater oral uptake
and greater daily loss of zinc by rats fed phenytoin at levels far in excess of therapeutic levels.
The anti-ulcerogenic drug cimetidine possesses several ligands and it is been shown that its binding
of Cu2. greatly enhances its binding to receptor sites on the rat brain (29). The possession of such
a wide range of ligands no doubt contribute to some of the recently reported biochemical properties
of cimetidine (30). Cu2.- and Ni2*-binding properties have been reported for famotidine, a structurally
similar anti-ulcerogenic drug (31).
o\
Fig. lab Structure of isoxicam and phenytoin
Perturbation of the levels of essential metal ions might not necessarily arise directly from
complexation by drugs but might arise from elevation of metal ion-binding proteins such as
metallothionein. Several agents, as diverse as whole body X-ray exposure (32) to induction by
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nonstearoidal antiinflammatory drugs (33) and the Ca2. ionophore calcimycin (34) elevate
metallothioneins levels. The induction in a yeast of cadystins, metallothionein-like peptides, by DDC
(35) might point to a similar induction of metallothionein in animals.
THE DEVELOPMENT OF CHELATING AGENTS AND THE MOBIUZATION OF METAL IONS
The use of chelating agents to counter the toxic action of metal ions began about fifty years in
England when 2,3-dimercaptopropanol was developed to counter arsenic-containing nerve gases. In
the twenty years or so that followed various other chelating agents and covering the full spectrum
from the hard bases, primarily EDTA and its congeners (Fig. 2), through the intermediate hardness
of polyamines, such as triethylenetriamine, to the soft bases (Fig. 3) were screened for ability to
mobilize a variety of toxic metal ions from the body. As inorganic biochemistry developed from the
mid-1970s onwards there has been a considerable expansion in the synthetic chemistry of chelating
agents and the forms in which they are used (Fig. 4). To enhance the uptake of chelating agents into
soft tissues, in which toxic metal ions have concentrated, chelating agents have been used in forms
such as: (i) lipophilic species, (ii) phagocytizable macromolecular chelating agents (MCAs) and (iii)
hydrophilic species entrapped in liposomes or even re-sealed erythrocytes. The extensive literature
covering these uses has been reviewed (10).
CH2 COOH HOOC- H2 C > CH2 CH2 X )n CHz CH2 N, CH2 COOH HOOC" H C RH-H--R H SH
n 0 EDTA R H R’ CH2OH
n 1= X NCHz.COOH, DTPA R H R’ CH2-SO3H
n 2. X NCH2 COOH, TTHA R R’ COOH
n 1. X O BADE R H R’ COOCzH
n= 1 X S BADS
Fig. 2 Structure of EDTA and congeners Fig. 3 2,3-Dimercaptans
CHELATING MOIE-rlES
2,3-DIMEICAPTAN PHEJOLIC
THIOL DITHIOCARBAMIC
FORM
PHOSPHONIC
HYDROXAMIC >N-ACETATE
SAUCYL
MOLECULAR
/WEIGHT
HIGH
MFPHILIC  ow\
HYDROPHIUC
Fig. 4 The moieties of chelating agents and the forms in which chelating agents might be used
Some therapeutic and potentially therapeutic applications of MCAs in combating toxic metal ions
have been briefly summarized (10). The accidental poisoning of small children who had ingested
ferrous sulphate tablets has led to the preparation and evaluation of hydroxamate-and
catechol-containing MCAs to block absorption of iron. By evaluation in mice it was established that
MCAs of around 106 Daltons formed from methacroyl moieties and bearing hydroxamate side-chains
had low toxicity and were effective. An effective blocking of enterohepatic recirculation of methyl-
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mercury(ll) in rural- dwelling Iraqis, who consumed grain which had been treated with a
mercury-based fungicide, was achieved by using a thiol-containing macromolecule.
Chelation-based procedures for removing toxic metal ions from bone, and also directing the uptake
of gamma-ray emitting radionuclides to bone, have also been sought. Whereas procedures for
selective direction of some chelating agents to soft tissues have been relatively successful, and are
the subject of further discussion below, the success in directing chelating agents to bone is perhaps
not quite so evident. As a fuller summary of the interaction of chelating agents, and chelated
radionuclides, with bone is given elsewhere (36) only a brief outline is given here. Uptake of
N-acetate-type chelating agents by bone appears to be low, 0.2% uptake, and is restricted to some
iminodiacetates which form calcium chelates with stability constants of log K 5. Presumably the
uptake of xylenol orange and calcein blue by bone is determined by the N,N-iminodiacetate moieties
they contain.
The affinity of tetracycline for calcified tissues presumably arises from keto-enol group generated
by the 11,12-diketone group (37). A highly effective uptake into bone of gamma-ray emitting
radionuclides, such as 99mTc, by using bis-phosphonates has become the basis of extensively
exploited procedures for the detection of excessive bone growth due to tumours (38) and Paget’s
disease (39). More recently some N-substituted phosphonates derived from
dimethylamino-dicyclopentadiene and dimethylaminonorborane have been evaluated and might also
become important vehicles for targeting radionuclides to bone (40).
To achieve a significant manageability of the use of chelation agents in decorporation therapy, their
usage has been summarized in Table 3. With the exception of HPO, the hydroxypyridones (Fig. 5),
these chelating agents are listed in the pharmacopoeia of many nations. The extent to which toxic
metal ions have been removed from the human body and thus been life-saving is not always easy
to assess. In spite of the reservations in the USA of the use of prophylactic chelation (41-43), from
laboratory studies on animals and the many cases of clinical usage, the evidence is substantial that
chelation therapy to combat the intake of toxic metal ions by humans is clearly beneficial. Perhaps
one of the most demonstrative studies of the benefits of chelation therapy is the marked reduction
of the incidence of bone sarcomas in mice, the recipients of ZnDTPA chelation therapy to counter
the radiobiological consequences of intravenously injected 239pu(IV) citrate (44). In humans the
benefits ofDFOA therapy in relieving the painful symptoms of aluminium uptake into bone have been
clearly demonstrated (45). DFOA has also clearly been of value for combating aluminium-induced
dialysis encephalopathy (46,47). Recently it has been reported that intramuscular injections ofDFOA
halted the decline in daily the living skills of patients with Alzheimer’s disease (48). However, the
role of aluminium in the aetiology of this disease continues to be controversial (49,50).
In the remainder of this section on the mobilization of toxic metal ions discussion will concentrate
primarily on the mobilization of transuranic elements, iron and cadmium, those areas where there
have been the greatest developments in chelation chemistry. The similarities in the hard acid
characteristics of Pu(IV) and Fe(lll) led to the evaluation of DFOA, and later other naturally occurring
Fe3.- selective chelating agents (siderophores), for ability to mobilize Pu(IV) from experimental
animals. Over about the last fifteen years numerous siderophores, encompassing catechol and
hydroxamic acid moieties, have been synthesized and screened for ability to mobilize cations of Pu
andAm from experimental animals. Some ofthe key developments in the evaluation of this extensive
synthetic programme, directed by Raymond at the University of California, have been briefly
summarized in a recent publication by Volf et al (51), an account of early chelation therapy in the
238 24 rat to counter uptakes of Pu and Am.
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Table 3 Application of chelating agents to mobilize toxic metal ions
Element
As(Ill) +
Au(I) +
Hg(ll) +
CH3-Hg(III) +
Cd(ll)
Cu0)
Pb(ll)
Fe(lll)
Ni(ll)
239pu(IV)
241Am(111)
AI(III)
CHELATING AGENTS
BAL PEN AcPEN* DMPS DMSA DDC TRIEN DTPA EDTA DFOA HPO
-I- +
-I- -I-
-I- -t-
/ +
+ +
*N-acetylpenicillamine
The success of Raymond’s highly innovative work can be judged by the reduction, by continuously
infused 3,4,3-LIHOPO (Fig. 6), of 241Am and 238pu in bones to <5% and 10% of the respective
levels in controls. The contents of the livers were reduced to <2% of the controls.
Raymond’s contribution to chelation therapy has been marked by the syntheses of ligands of a
variety of metal ions and of recent note is the synthesis of the lead(ll)-sequestering
bis(hydroxypyridinethione) ligand (Fig. 7) (52).
Almost parallelling Raymond’s extensive syntheses of siderophore-like chelating agents has been
the syntheses of chelating agents to counter the accumulation of iron in patients hypertransfused to
counter thalassaemia major. One of the prime motivators of the research has been the great costs
of DFOA- based chelation therapy. A detailed account of such syntheses, particularly of orally
administered chelators, is unwarranted here as adequate accounts, are in existence and particularly
from the clinician’s viewpoint (53).
The syntheses of lipophilic bidentates chelating agents such as the 3-hydroxy-pyridin-2-ones,
1-hydroxy- pyridin-2-ones and 3-hydroxy-pyridin-4-ones (11, 54) have been clearly major
developments in not only countering iron overload but also in expanding the use of ferric-selective
chelators in some other areas of life science research which are discussed later. Although these
HPOs have already entered some early clinical evaluations, their true value as orally administrable
chelating agents will require several years of clinical evaluation.
In a radical departure from the siderophore concept, Hegetscheiler and his colleagues have
synthesized 1,3,5-triamino-1,3,5-trideoxy-cis-inositol (55), and the N,N-dimethyl homologue (56), and
evaluated their chelation of iron(Ill), aluminium(lll) and copper(ll). This continued development of
chelating agents for use in intercepting iron is clearly necessary as it may aid us in furthering our
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Fig. 5 Hydroxypyridones Fig. 6 3,4,3-LIHOPO
CO- NCH2 CH2 NH- CO
Fig. 7 [1,2-ethyanediylbis(iminocarbonyl)]bis(1 -hydroxy-2(1H)-pyridine-2-thione
knowledge of the inorganic biochemistry of iron, a need suggested by the speculations of Stevens
and Kalkwarf (57). In their review they have speculated that western diets might lead to an
increased iron content of cells and tissues and thus may increase the risk of radiation-induced
cancer.
Jones (12) has summarized his extensive investigations of the structure-activity relationships of a
series of dithiocarbamic acids prepared to counter incorporated cadmium (Table 4 and Fig. 8). As
can be seen from Table 4, he has succeeded in obtaining significant reductions in the cadmium
burden of kidneys and liver by fine-tuning the amphilicity of the DDC derivatives.
As the chemistry of chelating agents has developed many accounts have detailed procedures for
synthesizing an ever extending array ofthe more common chelating agents. Foremost amongst these
studies have been accounts of the preparation of new PAPCs. Early attempts at modification were
no doubt hindered by the erroneous assumption that EDTA and its congeners had a limited
chemistry. A variety of derivatives of EDTA and DTPA have now been prepared by formation of
anhydrides and also by using reagents developed for activating carboxylic acids. The variety of
PAPCs range from those bearing substituents, such as lipophilic moieties and amino acids, on the
carboxylic groups (Fig. 9) to PAPCs, generally described as bifunctional chelating agents, bearing
substituents on the alkyl moieties. In many cases the structural modifications of EDTA and DTPA,
or in many cases the total synthesis of new forms of these chelating agents, have been applied in
what has become known as bioconjugate chemistry, a term used to describe the coupling of small
molecules to macromolecules such as polysaccharides (58,59) and proteins, primarily monoclonal
antibodies (MoAbs), for which there are now numerous references (60-64 and references therein).
In the last few years the developments in synthetic organic chemistry of the EDTA- and DTPA-like
molecules has become extensive and are briefly summarized in Table 5. There have also been
similar developments in the chemistry of N-substituted 1,4,7,10-tetrazacycloalkanes (Table 6). The
principal impetus in the development of these chelate-bearing MoAbs has been in nuclear medicine
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Table 4 Clearance of cadmium from mice by DDC derivatives of varying amphilicity and varying
molecular weight
DDC R Z X n Doseage Kidney# Liver
mmol/kg Cd Cd
DDC-1 Me CHOH 3 4.4 [9]* 0.46 0.97
DDC-2 C6H5 CHOH 3 0., [7] 0.99 0.96
DDC-3 4-Me-O-C6H5 CHOH 3 1 [5] 0.19 0.39
DDC-4 4-Me-O-C6H5 CHOH 5 112] 0.59 0.23
DDC-5 C6H5 -CH2C.H.CHOH.CH2OH 1 0.4[5] 0.39 0.38
O.Gal
DDC-6 Me C6H5 -CH2C.H.CHOH.CH2OH 1 0.4[5] 0.39 0.20
O.Gal
# No therapy, control animals, so taken as 1.0; frequency of injection; I-D-galactopyranosyl
.__H R ----Z---CH2-- I---CH2 H--IX In
SNa
Fig. 8 Basic structure of diethyldithiocarbamic acids
where there has been the quest for improved imaging
radiotherapies (65-67).
of tissues and also for highly directed
Further improvements in the syntheses of metal chelate-bearing proteins have continued. Of note
is a recently reported procedure for incorporation of chelating moieties into rationally selected sites
of proteins (68). Ebright et al (68) have achieved a high-efficiency incorporation of an EDTA-metal
complex into a protein. The key to this procedure was to use site-directed mutagenesis to produce
a unique solvent-accessible cysteine residue which can be derivatized by reaction with
N-(iodoacetyl)-p- phenylenediamine-EDTA:metal, a novel haloacetyl derivative of EDTA:metal.
A high specificity of antibodies for In(lll)EDTA-bearing proteins has been noted (69). On replacement
3+ 3+ of In by Sc or Ga3. on the EDTA-bearing antigen, the antibody binding was reduced by more
than three orders of magnitude. This reduced interaction of the antibody indicates that proteins
3+ bearing Sc3. or Ga3. instead of In might have significantly different conformations which have
3+ been brought about by different ligands being donated to Sc* or Ga Other important, and in
some cases earlier (10), developments in the chemistry of the PAPCs have involved producing them
in various lipophilic forms and also as nucleic acid-intercalating derivatives which could be used to
fragment nucleic acids into rationally-determined nucleotide sequences.
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NCHCH XCH CH)N
/ \Z HOOC.CH
R
CHY. COOH
Fig. 9 Structural variations of some recently synthesized PAPCs
Table 5 Structures of some PAPCs containing either EDTA or DTPA as the chelating group
Z
EDTA CH2COOH
EDTA-1 CH2COOH
EDTA-2 CH2COOH
H 0
p-NH.C6H5 0
H 0
Y R’ T
H H
H H
pSCN.BzH
EDTA-3 CH2COOH
EDTA-4 CH2COOH
EDTA-5 CH2COOH
EDTA-6 CH2CO.N,H
HOOC.CHCH2.SH
EDTA-7 CH2CO.NH H
HOOC.(H(CH2)2 SCH3
EDTA-8 CH2C,O H
OCH2.CH(SH).CH2SH
DTPA CH2COOH H
DTPA-1 CH2COOH H
DTPA-2 CH2COOH
DTPA-3 CH2CO.NH.Pr
DTPA-4 CH2CO.NH.Et H
DTPA-5 CH2--II-CH(Me) H
boll
DTPA-6 CH2COOH
DTPA-7 CH2COOH
-(CH2)2.COOH 0
TosyI.NH-(CH2)2 0
(CH3)2CH.CO- 0
H 0
H H
H H
H H
H H
0 H H
-(CH2)4NH2 1
H 1
0 H H
1 H H
CH2
H
H H H
1 H H H
1 H H
pNH2.Bz- 1 H Me
pSCN.Bz- 1 H Me
NCH2COOH
NCH2COOH
NCH2COOH
NCH2COOH
NCH2COOH
NCH2COOH
NCH2COOH
NCH2COOH
REF
(70)
(71)
(72)
(72)
(73)
(74)
(75)
(76)
(77)
(78)
(79)
(79)
(51)
(80)
(81)
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MONITORING THE INTRACELLULAR INORGANIC BIOCHEMISTRY OF Ca2+ BY USING
CHELATING AGENTS
Calcium ions are now known to be important regulators of intracellular metabolism. Increases in the
intracellular concentration of Ca2+ increases the activities of many enzymes and also regulates
various specialized cellular processes such as muscle contraction, phagocytosis and the secretion
of hormones such as insulin and histamine. The unravelling of the role of intracellular calcium in
processes such as phagocytosis and hormone secretion has been greatly facilitated by using two
major categories of chelating agents. In the first category are the polyether carboxylic antibiotics
which started to have a significant input into biochemical research at the cellular level about twenty
five years ago. These naturally occurring Ca2+-transporting ionophores, calcimycin and lasalocid,
formerly A23187 and X537A, are lipophilic and thus mediate the uptake of Ca2+ across cell
membranes by an electroneutral mechanism, in other words there is no energy-dependent transport
of Ca2+ across cell membranes. In the second category are several PAPCs which are taken up by
cells as the easily hydrolyzable acetoxymethyl esters. This type of membrane-permeable PAPC (Fig.
11) was originally synthesized by Tsien (85) with the aim of producing a Ca2+-selective fluorescing
chelating agent for quantitation of intracellular Ca2+. The applications of these various chemicals
have become numerous and much interesting data on the inorganic biochemistry of calcium ions
has been generated. By such procedures it has been possible to show young erythrocytes contain
62 nM Ca whereas much older cells contained 221 nM Ca2+ (86).
In more recent developments the Ca2*-selective PAPCs have been extended by preparation offorms
which can be photochemically activated inside cells and so produce controlled fast decrements in
intracellular concentrations of free Ca2. (87). By using fluorescence microscopy it is possible to
measure cytosolic Ca2* in individual cells loaded with these chelating agents (88). By attaching a
micro televison camera to a fluorescence microscope, Mohri and Hamaguchi (89) captured as series
of coloured images the propagation of transient Ca2. increase in sea urchin upon fertilization.
Inevitably there have been reports of the need for caution in ascribing some results to the actions
of these intracellular PAPCs (90). Modifications of the structure of chelating agents has not been
primarily restricted to PAPCs. By derivatizing DFOA to N-stearoyI-DFOA the chelating agent became
sufficiently lipophilic that it underwent biliary clearance (91). In more recent years DFOA has been
coupled to biocompatible polymers to prolong circulation in blood (92). Several groups have
synthesized mono- and diesters of dimercaptosuccinic acid and evaluated the derivatives for removal
of lead and cadmium (93). A recent review (94) has summarized the uses of DMSA and DMPS in
the People’s Republic of China where DMSA has also been used to treat intoxications by pesticides
and mushrooms.
NUCLEAR MEDICINE
Nuclear medicine has been one of the reat boons of the nuclear age. The principal radionuclide
99 used in imaging radiopharmaceuticals isU9mTc, t 6.02 h, the decay product of Mo, t, 66 h, which
is retained as molybdate on an alumina column. After elution as the pertechnate ion, TcO4, in sterile
saline, various reducing agents are used in the presence of a chelating agent, although occasionally
the ligand is not a chelating agent, to yield radiopharmaceuticals containing Tc(V), Tc(VI), Tc(lll) or
Tc(I)o By selection of suitable ligands it is possible direct the radionuclide to various organs or
diseased tissue and, also, ensure a rapid high uptake of the radionuclide into the target tissue into
contrast to a continuing circulation in blood. The contribution of slight structural variations of a series
of acetanilidoiminodiacetates upon the distribution of ssrnTc in mice has been summarized (95).
Also of note is an extensive study of the species-dependent distribution of 99mTc in various oxidation
states when complexed by 1,2-bisdimethylphosphinoethane (96). Further discussion of the use of
chelating agents in nuclear medicine appears elsewhere (10). A detailed account ofthe coordination
99m chemistry of radiopharmaceuticals has recently been issued (97). Although Tc-containing
radiopharmaceuticals are the major chemicals used in nuclear imaging of the body other chelated
67 111 radionuclides (principally Ga(lll) and In (111)) are also used. The recent development of other
188 188 62 2 68 8 90 o 115 115m parent/daughtergenerators, W/ Re, Zn/6 Cu, Ge/6 Ga, Sr/ Y and Cd/ In, extends
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Fig. 10 1,4,17,10-Tetraazacyclododecane
Table 6 Substituted 1,4,17,10-Tetraazacyclododecane PAPC analogues
R X R’ Ref
DOTA* CH2COOH
DOTA-1 CH2COOH CH2
DOTA-2 CH2COOH CH2
DOTA-3 CH2COOH CH2
DOTA-4 CH2COOH CH2
DOTA-5 CH2COOH CH2
DOTA-6 CH2Po(Me)OH
DOTA-7 CH2P(Me)OH CH2
DOTA-8 CH2PO(Bu)OH CH2
DOTA-9 CH2PO(C(Hs)OH
CH2COOH
Me.CH(OH)
CH2(OH).CH(OH)
CONH2Me
CONH2CH2CH2.O H
CONHCH2CH2.Me
CH2PO(Me)OH
CO.NHMe
CO.NHMe
CO.N(CH3)2
(82)
(82)
(82)
(82)
(83)
(84)
(84)
(84)
(84)
1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane
the diversity of the ligands which might be used to form imaging radiopharmaceuticals and
radiotherapies. In the last few years nuclear medicine has expanded further by using more selective
procedures to target radionuclides to tissues by using chelating agents chemically immobilized on
monoclonal antibodies. Although some of these MCAs have been used to improve targeting of
nuclear imaging, they have mainly been developed for radiotherapy. Torchilin and Kilbanov (98) have
recently reviewed the applications of antibody-linked chelating polymers in radiotherapy and
diagnosis.
MAGNETIC RESONANCE IMAGING
As is obvious from the account of the syntheses of many new PAPCs, the development of MRI has
led to many publications of the screening of chelating for use in MRI. Estimates have put the
contrast agent pharmaceuticals sales at around $2 billion (99). Several types of paramagnetic metal
ion-chelate complexes (magnetopharmaceuticals) have been examined as contrast-enhancing agents
in MRI. By chelating paramagnetic metal ions it is possible to reduce their toxicity and also target the
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paramagnetic ion to various organs in the body. By chelation of Gd(lll) by ligands such as DTPA it
is possible to raise its LD50 in mice from 0.38 mmol/kg (84) to more than 5 mmol/kg (99). Currently
chelated Gd(lll) is the principal paramagnetic species used to form magnetopharmaceuticals and
several Gd(lll)- containing magnetopharmaceuticals, such as the DTPA and DTPA-diglucamide
chelates, have been cleared for use clinical trials (100, 101). Chelated Mn(ll) has also been used
in humans (102). These hydrophilic agents are rapidly excreted by glomerular filtration through the
kidneys into urine with a biological half-life of 90 minutes. These hydrophilic chelates enhance brain
tumours because they are fed by capillaries which lack a blood-brain barrier, the tissue which blocks
passive diffusion of hydrophilic substances into neural tissue.
CH2 C00H ) z ( CHz COOH 2
,/OCHz
CHz Okk/,
"
R1
Fig. 11 Basic structure of Ca2+-binding chelates which fluoresce
Chelated Gd(lll) has also been used in various lipophilic DTPA forms which are cleared to the liver
and biliary duct (103-105) and as a variety of DTPA-bearing MCAs (106-108). By using antisera
raised to various forms of DTPA chelates of Gd(lll) evidence has been obtained which indicates that
Gd- DTPA is possibly bound by serum proteins (106). Four cases of anaphylactic response to
Gd-DTPA substantiate (109) this observation. As DTPA-based ligands are not totally kinetically inert
dissociation of the chelates can result in accumulation of Gd(lll) in bone and liver. In the quest
more stable forms of Gd(lll)-containing magnetopharmaceuticals, Parker’s group at the University
of Durham have demonstrated kinetic stability of various phosphinic acid analogues of DOTA (84).
In contrast to these DOTA derivatives, Sessler et al (110) have achieved kinetically inert complexes
of Gd(lll) by using texaphyrins, porphyrin-type macrocycles.
The preparation of such kinetically inert chelates will greatly extend the use nuclear magnetic
resonance procedures in medicine. Just as lanthanide shift reagents were of great benefit in
evaluating the structures of organic chemicals it can be expected that their introduction into
diagnostic medicine will be equally beneficial. Already the literature contains accounts of the
evaluation of such procedures in isolated organs and in experimental animals. Recently Bansal et
a/ (111) have established, in the rat, the potential of thulium(Ill)
1,4 7 10-tetrazacyclododecane-1,4,7,10-tetrakis(methylenephosphonate) as an in vivo shift reagent
for :Na+ in liver and other organs.
CHELATING AGENTSAS ANTIVIRAL,ANTIMICROBIAL, ANTINEOPLASIAL andANTIPARASITIC
CHEMOTHERAPEUTICS
The extent to which inorganic biochemistry can be exploited has been amply demonstrated by
utilizing the siderophore transport mechanism of cells as a drug-delivery system for therapies such
as Fo-lactams coupled to siderophores (112).
Two facts of note for a program of development of anti-viral and anti-tumour agents exploiting
aspects of inorganic biochemistry are the reported absence of copper from virus-specific enzymes
(113) and the low levels of essential trace elements in tumours in comparison to the surrounding
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healthy tissue (114). The recognition that inhibition of intracellular metalloenzymes by chelating
agents might lead to exploitable anti-viral and cytotoxic chemotherapy has prompted a great many
investigations (115). Whereas many of these studies have been restricted to laboratory evaluations,
some have been used prophylactically and of particular note was the beneficial administration of
thiosemicarbazones to people exposed to smallpox (116). Investigations ofthe anti-microbial aspects
of various chelating agents were among some of the earliest uses of chelating agents, such as
8-hydroxyquinoline (HQ, oxine), outside the analytical chemistry laboratory. Although some of these
early anti-microbial pharmaceutical preparations have now been withdrawn from the national
pharmacopoeia of many richer countries, their uses still continue in others because they are cheap
drugs. In many cases these studies have been restricted to pre-clinical investigations but in a few
cases the chelating agents have been used to counter infections of humans. Foremost amongst
these was the use of 5-methyl-8- hydroxyquinoline to counter cholera (117) and the use of CI/I-HQs
as amoebicides (118).
A variety of target metalloenzymes, and no doubt a variety of intracellular redoxes, make it difficult
to interpret the cytotoxic action of the various chelating agents which have been screened.
Investigations of the cytotoxic potential of chelating agents has continued with them formulated as
metal-free preparations, as chelates of essential trace elements, particularly first row transition
elements (119). Various bipyridyl chelates of several of these elements have been screened by
Franchetti and his colleagues for anti-tumour and anti-fungal properties (120-121). Inactivation of
ribonucleoside diphosphate reductase by chelation of Fe(ll) is a frequently suggested mechanism of
chelating agents such as thiosemicarbazones. The cytotoxic effects of omadine
(1-hydroxypyridine-2-thione) have been attributed to the chelation of iron (122).
Among one of the earliest developments in anti-neoplasial chelation therapy was the development
at the Imperial Cancer Research Fund in London of (+)-1,2-bis(3,5-dioxopiperazin-l-yl)propane (Fig.
12, ICRF 159, R=CH3). Investigations of the structure activity relationships ofsome close congeners
showed that ICR_F 192^(Fig..!2, R--_C,H5-) ws inactive. In investigations of the sequestration of
Mg:z+, Caz+, Mn’+, Fe3+, Ni:z+, Cu:Z+"and Zn;z+ by the diacid diamide hydrolysis products of ICRF
159 and ICRF 192, the only significant difference which could be shown was the weaker affinity of
the hydrolysis product of ICRF 159 for Zn2+ (123).
Several studies have investigated the chemotherapeutic value of DDC for HIV. In Germany an
extensive clinical study of patients receiving DDC intravenously has shown that it delays progression
of HIV infection at different sites and also acts to suppress secondary pathogens (124).
O,C CH2
HN HCH2 --N
OC CH
/CH2 CO
CO
Fig. 12 Basic structure of ICRF 159 and ICRF 192
The recognition that proliferating cells have a high requirement, for iron and the inhibition of a variety
of malignant cell lines by DFOA led to further evaluations of ligands synthesized by Hider. These
studies showed that 3-hydroxypyridin-4-ones could bring neoplastic cells to a high population of
synchronised proliferating cells with enhanced sensitivity to cell cycle-specific anti-tumour agents
(125).
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In about the last ten years chemotherapy to counter malaria has been extended to the use of HQ
derivatives (126) and ferric-selective chelating agents. In clinical studies intravenous infusion of
DFOA has been shown to hasten the clearance of parasitemia (127-128) and of particular benefit
was the raising from coma of children with cerebral malaria (127). Vanzyl et al (129) have proposed
that the anti-malarial action is due not only iron deprivation but also to the removal of iron from the
haemozoin crystal resulting in free radical generation and parasite death. Enhancement of the
lipophilicity of DFOA enhances the permeation of the chelating agent through the membrane of the
parasite (130). The oral uptake of 3-hydroxypyridin-4-ones could simplify anti-malarial chelation
therapy (131 ).
FREE RADICALS
For several years it has been recognised that oxygen radicals and other activated oxygen species,
sometimes collectively identified as reactive oxygen species (ROS), are involved in tissue injury and
the progression of several diseases (132). ROS are now implicated as the causative agents of aging,
cancer, multiple sclerosis, Parkinson’s disease and other diseases. An increased radical generation
and lipid peroxidation is perhaps the mechanism by which many xenobiotics such as paraquat,
ethanol, carbon tetrachloride and others exert toxicity. Research into these types of free radials has
become so extensive that at least two research journals are devoted to the study of free radicals in
medical sciences. The involvement of several of the essential trace elements, particularly in
metalloproteins and as low molecular weight complexed species, in the chemistry ROS has led to
the use of several chelating agents in probing the chemistry of ROS. The ROS, which include the
superoxide anion ( -O2), the hydroxyl radical (-OH), hydrogen peroxide and singlet oxygen (-02),
are generated inside cells as a result of normal electron transport or respiration. A variety of
processes ranging from normal cellular function through metabolism of xenobiotics to ionizing
radiation also lead to their formation.In a recent review Buettner (133) has presented a hierarchy of
free radicals and anti-oxidants.
The inter-relationships of free radicals and catalytic metal ions in human diseases have been
reviewed in detail (134). Investigations of metal ions and chelating agents in the chemistry of ROS
have been occurring for several years. A wide variety of topics have been studied and have ranged
from the formation of the hydroxyl radical in neutral solutions, from the reduction of hydrogen
peroxide by chelated iron, as in the following equation:
Fe(ll) + H202 > Fe(lll) + OH" + HO
to examination of chelated divalent transition elements as models of the enzyme superoxide
dismutase (SOD).
The formation of the hydroxyl radical in more neutral solutions, in strongly acidic solutions it is the
Fenton reaction, has been of interest for some years because ofthe recognition that tissue damage
occurs on the formation of ROS in microcirculation after re-starting blood flow after cardiac arrest,
stroke, organ transplant and haemorrhagic shock (135). Several publications in the proceedings of
Fifth Conference on Superoxide and Superoxide Dismutase, published in 1991, have dwelt on a
variety of aspects of chelation and oxygen radicals (136).
Among the topics included were: (i) the demonstration that deoxyribose damage was caused by
converting e into HO. in the presence of Fe(ll), Fe(lll) and Cu(ll); (ii) the SOD-like activity of aq
Cu(ll) complexed by carnosine, anserine and homocarnosine; (iii) determination of the SOD-like
activity of Cu(ll) complexed by cimetidine, an anti-peptic ulcer drug; (iv) oxidative degradation of
DNA and other biological macromolecules by catecholamines in the presence of Cu2*.
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Fig 13. Substituted Tris[2-aminoethyl]amines screened for SOD activity at their Fe(lll) and Cu(ll)
chelates.
The number of diseases in which ROS are implicated had by late 1989 exceeded sixty or more (137)
and such gathering pace in investigations of ROS-triggered diseases is in turn leading to further
investigations of roles for chelating agents in studying these diseases. Nagano et al (138), who
have briefly summarized the various forms of complexed copper which have SOD-like activity, have
synthesized a series of polyamines (Fig. 13) and shown the copper (11) chelates to have lower SOD
activity than Fe(lll) chelates. Several studies have demonstrated that DFOA can ameliorate tissue
damage but its value is somewhat limited because of its short circulating half-life. Evaluation of
DFOA- starch conjugate in ischemic rats demonstrated its prolonged circulation as well as a
reduction in microvascular failure (139).
In summary, there can be little doubt that chelating agents will still play a considerable role in
elucidating the inorganic biochemistry of the elements and also in combating some diseases.
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